Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Reawakening of ancient virus may trigger motor neurone disease

05 October 2015

By Hannah Somers

Appeared in BioNews 822

Reactivation of an ancient virus embedded in the human genome may trigger the onset of motor neurone disease (also known as amyotrophic lateral sclerosis or ALS).

Researchers have found that ALS patients with no family history of the disease had higher levels of the ancient retroviral gene HERV-K env than patients with other neurodegenerative diseases, such as Alzheimer's.

Human Endogenous Retroviruses (HERVs) are viruses that integrated themselves into human chromosomes during repeated infections over several million years of human evolution. They make up around eight percent of human DNA, but most have accumulated mutations that render them inactive. Occasionally, however, they can reactivate and cause disease.

In 2006, neurovirologist Dr Avindra Nath of the National Institute of Neurological Disorders and Stroke in Bethesda, Maryland, saw a young man who had both HIV, human immunodeficiency virus, and ALS – a degenerative disease that affects the neurons responsible for talking, walking and swallowing, among other motor functions. When the patient started taking antiretroviral drugs to treat his HIV, his ALS symptoms improved.

Following up this intriguing finding, Dr Nath noticed that reverse transcriptase activity (a sign of retrovirus infection) could be seen in ALS patients. 'I reasoned, if you have reverse transcriptase activity and you can't find an exogenous retrovirus, maybe there's an endogenous retrovirus,' said Nath.

Dr Nath and his team inserted either the whole HERV-K genome, or just the env gene, into human neurons in petri dishes. Once the virus (or viral protein) had integrated into the genome of the neuron and activated, it killed significant numbers of neurons.

The researchers also genetically engineered mice to express the virus in their neurons. The mice showed progressively worsening problems with balance and walking before dying prematurely. Analysis of their neurons after they died revealed structural changes associated with degeneration.

The findings, which were published in Science Translational Medicine, suggest that reactivation of the endogenous retrovirus HERV-K can trigger ALS in patients with sporadic (non-inherited) form of the disease.

Dr Nath is now launching a clinical study to see if ALS can be treated with antiretroviral drugs such as those used in the treatment of HIV. 'We haven't proven that the virus causes ALS; we've shown that the virus antiviral product may play a role in the pathophysiology of ALS,' Nath told The Scientist. 'Even if you don't know the cause, if you can find a key molecule in the pathway, you can block it and impact the course of the disease,' he said. 'We think we have a key molecule.'

SOURCES & REFERENCES
National Institutes of Health (press release) | 30 September 2015
 
The Guardian | 30 September 2015
 
The Scientist | 30 October 2015
 
Science Translational Medicine | 30 September 2015
 
Science (AAAS) | 30 September 2015
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

01 August 2016 - by Jenny Sharpe 
Donations from the ALS 'ice-bucket challenge' have funded research that has led to the discovery of new genes linked to the disease...
07 March 2016 - by Dr Özge Özkaya 
Ancient viral DNA could be helping our immune system fight off infections from modern viruses and other pathogens...

13 October 2014 - by Rhys Baker 
The US Food and Drug Administration (FDA) has awarded 'fast-track' status to a potential stem cell therapy for Amyotrophic Lateral Sclerosis (ALS), or motor neurone disease...
22 April 2013 - by Matthew Young 
A neural stem cell therapy aimed at treating the symptoms of amyotrophic lateral sclerosis (ALS) is set to advance in the USA, after the Food and Drug Administration (FDA) gave its approval for it to proceed to the next stage of clinical trials...
07 January 2013 - by Dr Tamara Hirsch 
Neural stem cells were shown to be effective against amyotrophic lateral sclerosis (ALS), or motor neurone disease, in 11 independent studies on mice with the disease...
02 April 2012 - by Dr Linda Wijlaars 
A clinical trial to test the safety of a stem cell treatment for amyotrophic lateral sclerosis, the most common form of motor neurone disease, suggests that the new therapy is safe and well-tolerated. Encouragingly, one of the 12 patients participating in the study showed some improvement, although the trial was not designed to test the treatment's efficacy...
26 September 2011 - by George Frodsham 
Researchers have identified a strong link between a genetic fault and two common neurological disorders. Two independent studies have found that the mutation is common in patients with amyotrophic lateral sclerosis (ALS) and patients with frontotemporal dementia (FTD), particularly if the disease is familial...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation